The cost associated with diagnostic testing using C6 peptide alone has been quoted, by one reference laboratory [6] , as $160.00, whereas the cost of a wholecell ELISA is typically half that amount [7] . It is likely that the use of pepC10 and C6 in combination will add to the cost of the immunoassay. Despite these costs, individuals exposed to European species and strains of Borrelia burgdorferi sensu lato may benefit from the C6-peptide-only immunoassay, because this antigen is highly conserved among B. burgdorferi sensu stricto, B. garinii, and B. afzelii [8] . In North America, the main drawback to whole-cell ELISAs has been their limited specificity [9] . If the VIDAS ELISA is as sensitive as the above-mentioned peptide-antigen assays, then one may consider an alternative approach: the use of these highly specific peptide-antigen assays to confirm results that are positive or equivocal by VIDAS ELISA. Given that most serology testing for Lyme disease is ordered in a setting of low pretest risk (!10%) [10] , the vast majority of tests will be negative; therefore, it is possible that it will be more cost-effective to use the immunoassay combination C6 and pepC10 to confirm results that are positive or equivocal by whole-cell ELISA, rather than using it for every patient. Additional data on the performance of the VIDAS ELISA in Bacon et al.'s study population would be useful in the determination of the feasibility of this alternative approach. 
